Novo Nordisk A/S (NVO) — Quality & forensics

As of 2026-09-18 — refreshed nightly. Closelook readings from an investment research diary, not ratings or advice.

The Closelook module scores

56 /100 composite · 7 modules · general weight set

Valuation 73
Quality 86
Growth 32
Balance sheet 49
Cash quality 34
Capital allocation 64
Momentum 46

Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.

Financial forensics — the academic screens

2.08 Altman Z-Score

Sits in the grey zone (1.81–2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.

5/9 Piotroski F-Score

Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.

-2.71 Beneish M-Score

Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.

Continue: the NVO chart & overview

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Novo Nordisk A/S's Closelook quality reading?

The composite reads 56/100 across 7 modules, as of 2026-09-18: valuation 73, quality 86, growth 32, balance sheet 49, cash quality 34, capital allocation 64, momentum 46. Closelook scores are research diary readings, not ratings or investment advice.

What is Novo Nordisk A/S's Altman Z-Score?

2.08, which sits in the grey zone (1.81–2.99) as of 2026-09-18. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.

What is Novo Nordisk A/S's Piotroski F-Score?

5 of 9, as of 2026-09-18. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.

What does Novo Nordisk A/S's Beneish M-Score indicate?

-2.71 — below the −1.78 manipulation-risk threshold, as of 2026-09-18. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.

Related in the Closelook universe

same Closelook index seat first, then Drug Manufacturers - General. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.